摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

D-glycero-D-galacto-Non-2-enonamide, 5-(acetylamino)-2,6-anhydro-3,5-dideoxy-N-[(4-methoxyphenyl)methyl]- | 1421960-07-7

中文名称
——
中文别名
——
英文名称
D-glycero-D-galacto-Non-2-enonamide, 5-(acetylamino)-2,6-anhydro-3,5-dideoxy-N-[(4-methoxyphenyl)methyl]-
英文别名
(2R,3R,4S)-3-acetamido-4-hydroxy-N-[(4-methoxyphenyl)methyl]-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxamide
D-glycero-D-galacto-Non-2-enonamide, 5-(acetylamino)-2,6-anhydro-3,5-dideoxy-N-[(4-methoxyphenyl)methyl]-化学式
CAS
1421960-07-7
化学式
C19H26N2O8
mdl
——
分子量
410.424
InChiKey
UDDYFSPGSSPHPJ-QBBQCFRVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.3
  • 重原子数:
    29
  • 可旋转键数:
    8
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    158
  • 氢给体数:
    6
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Structure-Based Design and Synthesis of C-1- and C-4-Modified Analogs of Zanamivir as Neuraminidase Inhibitors
    摘要:
    In order to exploit the 430-cavity in the active sites of neuraminidases, 22 zanamivir analogs with C-1 and C-4 modification were synthesized, and their inhibitory activities against both group-1 (H5N1, H1N1) and group-2 neuraminidases (H3N2) were determined. Compound 9f exerts the most potency, with IC50 value of 0.013, 0.001, and 0.09 mu M against H3N2, H5N1, and H1N1, which is similar to that of zanamivir (H3N2 IC50 = 0.0014 mu M, H5N1 IC50 = 0.012 mu M, H1N1 IC50 = 0.001 mu M). Pharmacokinetic studies of compound 9f in rats showed a much longer plasma half-life (t(1/2)) than that of zanamivir following administration (po dose). Molecular modeling provided information about the binding model between the new inhibitors and neuraminidase, with the elongated groups at the C-1-position being projected toward the 430-loop region. This study may represent a novel starting point for the future development of improved antiflu agents.
    DOI:
    10.1021/jm3009713
点击查看最新优质反应信息

文献信息

  • Structure-Based Design and Synthesis of C-1- and C-4-Modified Analogs of Zanamivir as Neuraminidase Inhibitors
    作者:Enguang Feng、Woo-Jin Shin、Xuelian Zhu、Jian Li、Deju Ye、Jiang Wang、Mingyue Zheng、Jian-Ping Zuo、Kyoung Tai No、Xian Liu、Weiliang Zhu、Wei Tang、Baik-Lin Seong、Hualiang Jiang、Hong Liu
    DOI:10.1021/jm3009713
    日期:2013.2.14
    In order to exploit the 430-cavity in the active sites of neuraminidases, 22 zanamivir analogs with C-1 and C-4 modification were synthesized, and their inhibitory activities against both group-1 (H5N1, H1N1) and group-2 neuraminidases (H3N2) were determined. Compound 9f exerts the most potency, with IC50 value of 0.013, 0.001, and 0.09 mu M against H3N2, H5N1, and H1N1, which is similar to that of zanamivir (H3N2 IC50 = 0.0014 mu M, H5N1 IC50 = 0.012 mu M, H1N1 IC50 = 0.001 mu M). Pharmacokinetic studies of compound 9f in rats showed a much longer plasma half-life (t(1/2)) than that of zanamivir following administration (po dose). Molecular modeling provided information about the binding model between the new inhibitors and neuraminidase, with the elongated groups at the C-1-position being projected toward the 430-loop region. This study may represent a novel starting point for the future development of improved antiflu agents.
查看更多